Abstract
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of donepezil are reviewed. Donepezil is a synthetic noncovalent reversible inhibitor of acetylcholinesterase (AChE) for the treatment of mild to moderate dementia associated with Alzheimer's disease. In contrast to tacrine hydrochloride, the only comparable agent currently approved by FDA, donepezil exhibits a relatively high degree of selectivity for neuronal AChE as opposed to butyrylcholinesterase. It has a half-life of 60 hours in young adults and 104 hours in elderly patients. In clinical trials, donepezil has been associated with significant improvements in Alzheimer's Disease Assessment Scale-cognitive subscale and Clinical Interview-Based Impression of Change scores. The most common adverse effects associated with donepezil are nausea, diarrhea, anorexia, and vomiting, which are most likely to occur during dose initiation or adjustment. Hepatotoxicity, a dose-limiting adverse effect that sometimes requires discontinuation of tacrine, has not been reported with donepezil. Donepezil does not appear to interact with theophylline, cimetidine, warfarin, or digoxin. Ketoconazole and quinidine inhibit the me...Continue Reading
Citations
Nov 30, 2000·Current Treatment Options in Neurology·A S Schachter, K L Davis
Aug 7, 2002·Clinical Pharmacokinetics·Michael W JannGary W Small
Apr 28, 2005·Expert Review of Neurotherapeutics·David S Geldmacher
Oct 18, 2007·Expert Review of Neurotherapeutics·Boben Benjamin, Alistair Burns
Feb 4, 2009·Acta Clinica Belgica·R I R Dierckx, M F J Vandewoude
Feb 15, 2013·Clinical Pharmacokinetics·Muriel Noetzli, Chin B Eap
Jun 29, 2013·Journal of Biomolecular Structure & Dynamics·Flávio Roberto PinsettaCarlos Henrique Tomich de Paula da Silva
Sep 3, 2016·American Journal of Alzheimer's Disease and Other Dementias·Ahmet Turan IsikCansu Usarel
Jul 26, 2018·Journal of Medicinal Food·Yubeen KwonJong Hoon Ryu
Mar 23, 2019·Journal of Biomolecular Structure & Dynamics·Anas ShamsiAsimul Islam
Apr 22, 2019·Biomolecules & Therapeutics·Jihyun KimJong Hoon Ryu
May 16, 2006·CNS Drugs·Philippe BordierAlexia Lafitte
Aug 3, 2005·Drugs & Aging·Philippe BordierAlexia Lafitte
Dec 29, 2000·Journal of the American Geriatrics Society·M M VerricoA L Towers
Aug 31, 1999·The Annals of Pharmacotherapy·G ShepherdR Edwards
May 10, 2000·Drugs & Aging·M Dooley, H M Lamb
Apr 28, 2005·Expert Review of Neurotherapeutics·Christopher M Young, Robert L Findling
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Ben Seltzer
Mar 13, 2014·Human Psychopharmacology·Hirofumi IgetaToshiyuki Someya
May 11, 2012·American Journal of Alzheimer's Disease and Other Dementias·Ahmet Turan IsikUmit Ateskan
Jan 18, 2014·British Journal of Clinical Pharmacology·Muriel NoetzliChin B Eap
Apr 15, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·Shuji ShimizuMasaru Sugimachi
Mar 2, 2019·Current Alzheimer Research·Eva MezeiovaJan Korabecny
Mar 28, 2012·Internal Medicine·Ahmet Turan IsikEmine Aydemir
Feb 7, 2017·Phytotherapy Research : PTR·Sunhee LeeJong Hoon Ryu
Nov 28, 2018·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Tahir MuhammadMyeong Ok Kim
Nov 19, 2013·Biomolecules & Therapeutics·Hyung Eun LeeJong Hoon Ryu
May 19, 2007·Journal of Biomolecular Structure & Dynamics·Carlos H T P da SilvaC A Taft
Dec 17, 2020·Brain Sciences·Jogender MehlaDiksha Diksha
Feb 12, 2021·BMC Neurology·Hideki ShimuraTakao Urabe
Jan 20, 2020·International Journal of Biological Macromolecules·Anas ShamsiAsimul Islam
Jul 8, 2020·ACS Chemical Neuroscience·Mehrnoosh NikpourSina Andalib
Oct 17, 2020·Therapeutic Drug Monitoring·Yoshiyuki KagawaTomokazu Obi
Feb 8, 2020·Journal of Natural Products·Sang-Bin LeeHyun Ok Yang